Kilpatrick K E, Wring S A, Walker D H, Macklin M D, Payne J A, Su J L, Champion B R, Caterson B, McIntyre G D
Department of Molecular Sciences, Glaxo Wellcome, Research Triangle Park, NC 27709, USA.
Hybridoma. 1997 Aug;16(4):381-9. doi: 10.1089/hyb.1997.16.381.
Affinity matured murine monoclonal antibody producing cell lines can now be rapidly generated using a novel repetitive, multiple site immunization strategy designated RIMMS. RIMMS capitalizes on rapid hypermutation and affinity maturation events which occur in B cell populations localized within secondary lymphatic tissue early in response to antigenic challenges. A murine myeloma cell line, P3XBcl-2-13, stably transfected with Bcl-2, enhances the outgrowth of hybridomas following somatic fusion with immune lymphocytes isolated from pooled peripheral lymph nodes (PLN) 8-14 days after the initial immunization. Immunizations somatic fusion, screening and isolation of affinity matured IgG secreting monoclonal antibody cell lines occur within a one month time period. By using RIMMS, we have been able to expedite the isolation of affinity matured monoclonal antibodies to numerous antigens, including a drug hapten.
利用一种名为RIMMS的新型重复性多位点免疫策略，现在可以快速生成亲和力成熟的鼠源单克隆抗体产生细胞系。RIMMS利用了在抗原刺激早期位于次级淋巴组织内的B细胞群体中发生的快速超突变和亲和力成熟事件。一种稳定转染了Bcl-2的鼠骨髓瘤细胞系P3XBcl-2-13，在初次免疫后8-14天与从汇集的外周淋巴结（PLN）分离的免疫淋巴细胞进行体细胞融合后，可增强杂交瘤的生长。亲和力成熟的分泌IgG单克隆抗体细胞系的免疫、体细胞融合、筛选和分离在一个月的时间内完成。通过使用RIMMS，我们已经能够加快针对多种抗原，包括药物半抗原的亲和力成熟单克隆抗体的分离。
